11 completed, 1 terminated, 1 withdrawn. 13 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 11, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Carcinoma, Islet Cell: new trials by email Literature Review of Carcinoma, Islet Cell trials Research Report on Carcinoma, Islet Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Laser Tissue Welding - Distal Pancreatectomy Sealing Study Distal Pancreatectomy Sealing Using LTW - Pancreatic Tumor, Benign, Pancreatic Neoplasms | Phase 1 | Completed | Laser Tissue Welding, Inc. | 11 | 2018-01-01 | 2022-04-06 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer BBI608, Nab-paclitaxel, Gemcitabine - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 139 | 2014-08-01 | 2023-11-18 |
| Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery temozolomide, pazopanib hydrochloride - Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma | Phase 1 / Phase 2 | Completed | Northwestern University | 29 | 2011-12-12 | 2021-08-05 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-10-01 | 2016-07-15 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma | Phase 1 | Completed | University of Southern California | 19 | 2010-06-01 | 2016-06-13 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma | Phase 1 | Completed | Mayo Clinic | 96 | 2004-12-01 | 2024-08-21 |
| Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors 90Y-DOTA-tyr3-OCTREOTIDE - Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor | Phase 1 | Completed | O'Dorisio, M S | 27 | 2002-01-01 | 2016-06-21 |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer trastuzumab, tipifarnib - Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2000-06-01 | 2013-02-11 |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum floxuridine, leucovorin calcium, oxaliplatin - Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2000-04-01 | 2011-04-26 | |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 1999-08-01 | 2013-02-28 |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer yttrium Y 90-edotreotide - Brain and Central Nervous System Tumors, Breast Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 60 | 1998-01-01 | 2013-05-01 |
| Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer indium In 111 pentetreotide - Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis | Phase 1 | Terminated | Yale University | 35 | 1996-10-01 | 2014-07-02 |
Insulinoma (10) · Glucagonoma (9) · Somatostatinoma (8) · Carcinoma, Medullary (7) · Gastrinoma (7) · Vipoma (7) · Pheochromocytoma (6) · Adenoma, Islet Cell (5) · Carcinoma, Merkel Cell (5) · Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Renal Cell (5) · Pancreatic Neoplasms (5) · Breast Neoplasms (4) · Neoplasms (4)
Adenocarcinoma (13) · Carcinoma (13) · Digestive System Diseases (13) · Endocrine System Diseases (13) · Neoplasms by Histologic Type (13) · Neoplasms by Site (13) · Neoplasms, Glandular and Epithelial (13) · Digestive System Neoplasms (12) · Endocrine Gland Neoplasms (12) · Pancreatic Diseases (12) · Adenoma (11) · Neoplasms, Germ Cell and Embryonal (11) · Neuroectodermal Tumors (11) · Carcinoma, Neuroendocrine (10) · Neoplasms, Nerve Tissue (10)
Everolimus (2) · Leucovorin (2) · Oxaliplatin (2) · Temozolomide (2) · Trastuzumab (2) · 130-nm albumin-bound paclitaxel (1) · 90Y-octreotide, DOTA-Tyr(3)- (1) · Acetates (1) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Floxuridine (1) · Fluorouracil (1) · Gemcitabine (1) · High-Energy Shock Waves (1) · Interleukin-12 (1)
National Cancer Institute (NCI) (3) · Laser Tissue Welding, Inc. (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Northwestern University (1) · Novartis Pharmaceuticals (1) · O'Dorisio, M S (1) · Sumitomo Pharma America, Inc. (1) · University of Southern California (1) · Vanderbilt-Ingram Cancer Center (1) · Yale University (1)
United States (12)
Agustin Garcia (1) · Anthony W. Tolcher, MD (1) · Halla Nimeiri (1) · James Yao (1) · John R. Murren, MD (1) · Jordan Berlin, M.D. (1) · Julian R. Molina, M.D., Ph.D. (1) · Larry K. Kvols, MD (1) · Leonard B. Saltz, MD (1) · M. Sue O'Dorisio, MD, PhD (1) · William Carson (1)
P30CA016672 (1), R44CA203052 (1), U01CA062461 (1), U01CA076576 (1)